Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19

Mostrar otras versiones (1)

BACKGROUND: Despite limited and conflicting data on the use of hydroxychloroquine in patients with Covid-19, the U.S. Food and Drug Administration has authorized the emergency use of this drug when clinical trials are unavailable or infeasible. Hydroxychloroquine, alone or in combination with azithr...

Descripción completa

Detalles Bibliográficos
Autores principales: Magagnoli, Joseph, Narendran, Siddharth, Pereira, Felipe, Cummings, Tammy, Hardin, James W., Sutton, S. Scott, Ambati, Jayakrishna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276049/
https://www.ncbi.nlm.nih.gov/pubmed/32511622
http://dx.doi.org/10.1101/2020.04.16.20065920

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276049/
https://www.ncbi.nlm.nih.gov/pubmed/32511622
http://dx.doi.org/10.1101/2020.04.16.20065920

Ejemplares similares